Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drugs or need for dose adjustments based on the known vicriviroc drug-drug interaction profile. The studies will enroll approximately 375 patients each at more than 160 sites in North America, South America, Europe, Australia and South Africa.

"As a next-generation HIV entry inhibitor, vicriviroc has the potential to benefit a broad range of patients by offering a potent, sustained viral response and a single once-daily dose in combination with optimized background therapy," said Robert J. Spiegel, M.D., chief medical officer and senior vice president, Schering-Plough Research Institute. "There is an urgent need for new antiretroviral agents with novel mechanisms of action and we look forward to the further clinical evaluation of vicriviroc in these large global studies."

About the VICTOR-E3 and VICTOR-E4 Phase III Studies

VICTOR-E3 and VICTOR-E4 are identically designed, randomized, double- blind, placebo-controlled, parallel group, multicenter studies of vicriviroc in adult treatment-experienced patients infected with CCR5-tropic HIV virus (no detectable CXCR4-tropic or dual/mixed CCR5/CXCR4-tropic virus at screening).

The primary efficacy endpoint of the studies will be the proportion of patients with plasma HIV-1 RNA less than 50 copies/mL at week 48. Key secondary endpoints, each measured at 48 weeks, include the proportion of patients with less than 400 copies/mL of plasma HIV-1 RNA, mean change from baseline in plasma HIV-1 RNA (log10 copies/mL) and mean change from baseline CD4+ count. All efficacy endpoints will also be evaluated at week 24.

Patients in VICTOR-E3 and VICTOR-E4 must have documented resistance to at least two of the three antiretroviral drug classes (NRTI, NNRTI or PI)(2-4) or 6 months or more of experience with at least two of the following: one NRTI, one NNRTI or two PIs (excluding low-dose ritonavir); and must have plasma HIV- 1 RNA levels above 1000 copies/mL. The optimized background therapy must include a protease inhibitor boosted by ritonavir and at least two drugs that are active, based on susceptibility testing. The optimized background therapy will be chosen by the investigator based on results of drug susceptibility tests performed at screening, patient history of prior antiretroviral drug use and drug toxicity.

The VICTOR-E3 and VICTOR-E4 studies will also evaluate the safety and tolerability of vicriviroc compared to placebo, each given in combination with an optimized background therapy. An independent, external Data Safety Monitoring Board (DSMB) will review study data on a regular basis to assure continued safety of the participants.

For more information about the VICTOR-E3 and VICTOR-E4 clinical studies, please visit http://www.clinicaltrials.gov, search term: vicriviroc.

About Schering-Plough

Schering-Plough is a global science-based health care company with leading prescription, consumer and animal health products. Through internal research and collaborations with partners, Schering-Plough discovers, develops, manufactures and markets advanced drug therapies to meet important medical needs. Schering-Plough's vision is to earn the trust of the physicians, patients and customers served by its approximately 33,500 people around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the timing of clinical trials, the company's plans and the potential for vicriviroc. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's second quarter 2007 10-Q.

References:

1 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results (TUAB102); International AIDS Society 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.

2 NRTI - nucleoside reverse transcriptase inhibitor

3 NNRTI - non-nucleoside reverse transcriptase inhibitor

4 PI - protease inhibitor


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , March 28, 2017  Akcea Therapeutics, a subsidiary ... to the company,s board of directors: ... Partners. Mr. Gabrieli will serve as chairman of the board ... former chief commercial officer of Forest Laboratories. ... Biolink Partners. "We are excited to ...
(Date:3/28/2017)... SAN FRANCISCO , March 28, 2017 ... is expected to reach USD 8.0 billion by 2025, ... Inc. The increasing incidence of infectious diseases and cancer ... for use in disease diagnosis over the coming years. ... the usage of autologous and allogenic stem cell therapy, ...
(Date:3/27/2017)... LONDON , March 27, 2017 ... require to better understand Eli Lilly and its partnering interests ... Alliance since 2010 report provides an in-depth insight into the ... companies. On demand company reports are prepared upon ... deal and company data. The report will be ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... ... Paul Yost, will begin serving as new board chair for Orange County health ... will serve the remainder of soon-to-be former chair Mark Refowitz’s term, which runs ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric ... Inc. is thrilled to offer the recently FDA-approved Obalon Balloon System to his ... to SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu ...
(Date:3/28/2017)... Albertson, NY (PRWEB) , ... March 28, 2017 , ... Oily skin is a common ... with Advanced Dermatology has a lot to offer to the discussion of dealing ... good news is that there are many home remedies that can help remove the oily ...
(Date:3/27/2017)... ... March 27, 2017 , ... New patients who have sleep apnea ... with or without a referral. Sleep apnea is often left untreated because patients are ... headaches and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep ...
Breaking Medicine News(10 mins):